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Abstract: Induction chemotherapy is often the first therapeutic intervention for acute myeloid leukemia (AML). Evaluation of post induction bone marrow provides critical information for clinical management; in general increased
blast counts or increased marrow cellularity is an ominous sign, suggestive of ineffective therapy, and may warrant
additional rounds of chemotherapy. However, increased blasts alone are not necessarily predictive of recurrent/persistent disease. Here we report a very unusual observation in a case of AML with a core binding factor beta (CBFB)
rearrangement. In this case the day 21 post-induction marrow biopsy showed a high blast count (approximately
20%), however, subsequent fluorescence in-situ hybridization studies were negative for CBFB rearrangement. We
compared this finding to post-induction marrows from a series of 6 AML cases with CBFB rearrangements, none
of which showed an increased blast count. This case illustrates that increased blast counts, even those comprising 20% of cells, are not de facto evidence of induction failure, and that correlation with ancillary studies such as
fluorescence in-situ hybridization should be used to distinguish a persistent neoplastic clone, from a brisk marrow
recovery.
Keywords: Core binding factor beta, acute myeloid leukemia, inv(16), day 21 marrow, post induction, DUP98,
t(11;20)(p15;q11.2)

Introduction
Acute myeloid leukemia (AML) is a hematologic
malignancy resulting from clonal expansion of
myeloid precursors that involves peripheral
blood, bone marrow, as well as extramedullary
tissues. AML is the most common acute leukemia in adults and was estimated to cause over
10,000 deaths in 2012 [1]. According to current 2008 WHO classification, a diagnosis of
AML can be made when blasts exceed 20% in
either peripheral blood or bone marrow.
The initial treatment of nearly all subtypes of
AML is induction chemotherapy. The actual regimens are based on patients’ age, performance
status and prior history of myelodysplasia or
cytotoxic therapy. The purpose of induction is
to reduce of tumor burden and restore normal
hematopoiesis of the bone marrow. Postinduction bone marrow evaluation is recommended 7 to 10 days after induction, or commonly known as “Day 14 bone marrow” or less

commonly “Day 21 bone marrow”, depending
on various induction regimens. Important clinical decisions are based on the findings from
post-induction bone marrow, and patients who
do not show an appropriate reduction in bone
marrow blasts or bone marrow cellularity are
often given additional rounds of induction
chemotherapy.
Inversion 16, or t(16;16) involves the Core
Binding Factor Beta (CBFB) gene and is considered as a favorable translocation with good outcome of induction chemotherapy [2]. Here we
report an unusual observation of a high percentage of non-neoplastic myeloblasts (approximately 20% of total marrow cells) in a postinduction bone marrow from an AML case with
CBFB rearrangement.
Case report
The patient was a 56 year-old woman with a
past medical history of hypothyroidism and dia-
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Figure 1. Increased blasts in the aspirate and core biopsy of the Day 21 bone marrow. A, B. The Wright-Giemsa
stained marrow aspirate contains increased number of immature precursors, characterized by slightly irregular
nuclear contours, fine chromatin, prominent nucleoli, and moderate amounts of light basophilic cytoplasm. (Original
magnification 1000x). C, D. Hematoxylin-Eosin stained core biopsy shows pockets of immature precursors with very
little maturation of granulocytic lineage (Original magnification 600x).

betes mellitus presented to an outside hospital
with progressive fatigue. Laboratory tests
showed severe pancytopenia, including a
hemoglobin level of 4 g/dL. A bone marrow
aspirate was obtained, which showed “acute
leukemia”.
The patient was transferred to our institution
and her CBC showed the following: WBCs 2.5 x
109/L, RBCs 3.08 x 1012/L, Hemoglobin 10.3
g/dL, Mean corpuscular volume (MCV) 96.4 fL,
Platelets 43 x 109/L. An in-house bone marrow
biopsy showed 12% blasts and eosinophils with
abnormal granulations. Flow cytometry showed
that 31% of analyzed events were CD34positive blasts with co-expression of CD13,
CD117, CD33, HLA-DR, and negative for CD14,
CD56, CD64, CD2, or CD5. The full cytogenetic
karyotype was: 46XX,t(11;20)(p15;q11.2),inv
(16)(p13.1q22)[9]/47,idem,+8[7]/46XX[4] and
Fluorescent In Situ Hybridization (FISH) per4499

formed on metaphase cells confirmed presence of CBFB rearrangement and trisomy 8.
These findings were diagnostic of a AML with
inv(16)/CBFB rearrangements, and the patient
was enrolled in CALGB 10801, a phase II clinical trial, and received 7+3 induction plus 13
doses of dasatinib.
A post-induction bone marrow biopsy was performed at Day 21. Concurrent CBC was as follows: WBCs 0.7 x 109/L, RBCs 2.41 x 1012/L,
Hemoglobin 7.7 g/dL, Hematocrit 21.5%, MCV
89.3 fL, Red cell distribution width (RDW-CV)
13.9%, Platelets 19 x 109/L. Review of peripheral blood showed pancytopenia with rare circulating blasts. The marrow aspirate and core
biopsy revealed a hypocellular specimen with
19% blasts by manual differential count (Figure
1). The blasts were characterized by fine chromatin, large nucleoli, and moderate amount of
light basophilic cytoplasm. Flow cytometric
Int J Clin Exp Pathol 2014;7(7):4498-4502
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Figure 2. Increase of blasts identified by flow cytometry. Twenty-one percent of total cells are blasts that are positive
for CD34, CD117, and CD33.

Table 1. Blast Counts of Day 21 Marrows of AML with
CBFB rearrangements
No Age/Sex D21 Blast%
1$
56/F
21
2
62/F
2
3
24/F
2
4
71/F
1
5
55/M
4
6
48/M
2
7* 29/M
0

D21 FISH F/U FISH (interval)
Negative
Negative
0.33% Negative (+12 days)
N/A
Negative
Negative
Negative
Negative
Negative
N/A
Negative
1.50%
0.30% (+22 days)

D21: Day 21; FISH: Fluorescent In Situ Hybridization; F/U: follow-up;
N/A: Not applicable. $The currently reported case. *This patient had
allogeneic stem cell transplantation and post-transplant FISH result
(143 days after the initial induction chemotherapy) was negative.

immunophenotyping showed that 21% of total
cells were blasts with partial co-expression of
CD34, CD33, CD64 and CD117 (Figure 2).
Based on these findings the case was called
‘persistent AML’ and the patient received reinduction chemotherapy with 5+3 per protocol.
However, in the days following morphologic
review of the bone marrow, FISH studies were
performed and showed no evidence CBFB rearrangement. These latter results are most consistent with increased blasts due to a recovering marrow as they did not harbor the clonal
CBFB rearrangement identified at diagnosis.
Following induction, the patient received three
cycle of high dose cytarabine and dasatinib
consolidation chemotherapy followed with
dasatinib maintenance therapy. All subsequent
bone marrows (up to 14 months post induction)
4500

showed no evidence of recurrent leukemia
by morphology and cytogenetics/FISH.
These findings further support that the
increased bone marrow blasts seen in the
post induction marrow were not part of the
AML clone.
Marked increases of non-neoplastic
myeloblasts in post-induction is a rare
observation. A review of the English literature showed a single report of increased
non-neoplastic blasts in the peripheral
blood around Day 21 post induction [3].
Interestingly, this case is also an AML
patient with CBFB rearrangement [3]. One
possible explanation for increased nonneoplastic blasts post-induction is that, compared to the Day-14 marrows, Day 21 marrows
have higher percentage of non-neoplastic
blasts in AML cases with CBFB rearrangements. To test this hypothesis, we collected all
the consecutive Day 21 marrows from AML with
CBFB rearrangements at Washington University
in last three years. There were 7 cases in total
with 3 male and 4 female (Table 1). Except for
the current case (Case 1), the other 6 cases did
not show increased blast counts and the blast
percentage ranged from 0-4% with an average
of 1.8%. In comparison, Day 14 marrows from
eleven cases of AML with CBFB rearrangements during the same time period had blast
counts ranging from 0% to 4% (specifically, 5
cases with 0%, 3 cases with 1%, 1 case with
2%, 1 case with 3% and 1 case with 4% blasts,
respectively). The average blast count of the
Int J Clin Exp Pathol 2014;7(7):4498-4502

High counts of non-neoplastic blasts in day 21 marrow
eleven Day 14 marrows was 1.1%. The blast
percentages between Day 21 and Day 14 marrows were not significantly different (p = 0.30).
Even though limited by the number of available
cases, our data argue against the hypothesis
that in general, Day 21 bone marrows show
higher blast counts than that of Day 14 marrows in AML cases with CBFB rearrangements.
Discussion
CALGB 10801 is an on-going phase II clinical
trial to assess the safety and tolerability of
dasatinib with induction, consolidation and
maintenance chemotherapy in newly diagnosed acute myeloid leukemia (http://www.
clinicaltrials.gov/, Identifier: NCT01238211).
The induction therapy is one course of 7+3
(daunorubicin, cytarabine) plus dasatinib. If
Day 21 bone marrow shows cellularity ≥ 20%
and leukemic blasts ≥ 5%, a re-induction therapy with 5+3 (cytarabine, daunorubicin) plus
dasatinib would be given. Unfortunately, our
patient had received the re-induction before
FISH results were available. Consolidation therapy is 4 courses of high dose cytarabine +
dasatinib. Our patient had been treated with
only 3 courses due to neutropenia and thrombocytopenia. Maintenance therapy is 12 courses of dasatinib.
AML with inv(16) or t(16;16) involves CBFB and
MYH11 genes and usually shows both monocytic and granulocytic differentiation with the
characteristic abnormal eosinophils containing
basophilic granules. Inv(16) or t(16;16) is favorable translocation and the group has a complete remission rate of approximately 85%,
which is not affected by additional cytogenetic
abnormalities [2].
Secondary cytogenetic abnormalities are
reported in approximately 40% cases of AML
with CBFB rearrangements, common forms
including +22, +8, del(7q), and +21 [4]. t(11;20)
(p15;q11.2) is a rare recurrent nonrandom
translocation, and was reported to result in
NUP98/TOP1 fusion protein [5]. It has been
rarely reported in AML and other myeloid neoplasms. Our case is the first reported t(11;20)
(p15;q11.2) case in an AML with CBFB rearrangement. NUP98 (Nucleoporin 98 gene) on
chromosome 11 is a component of nuclear
pore complex. To date, translocations involving
NUP98 have been reported with 28 different
partner genes in hematologic malignancies,
4501

predominantly myeloid neoplasms [6]. NUP98
was believed to have roles in transcription, and
cell cycle regulation, and Murine models of
NUP98 fusion proteins have shown evidence of
leukemogenicity [6].
A marked increase of non-neoplastic blasts is a
rare observation in post-induction bone marrow, and occurs due to an unknown mechanism. Such cases could represent a diagnostic
pitfall, if cytogenetic results are not available,
and could result in unnecessary chemotherapy.
If unexpectedly high blast counts are seen in a
post-induction bone marrow biopsy from
patients with favorable cytogenetic abnormalities, such as t(8;21) and inv(16), close observation of the blast count trend and correlation
with cytogenetic findings should be considered.
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